Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01594983 · ClinicalTrials.gov registry record · Phase 2
A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 58
- Enrollment target
NCT01594983 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 58 participants.
The verdict
NCT01594983, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 58 participants
- Enrollment target
Study Summary
This study is to determine a dose response signal for LCQ908 monotherapy and to assess the efficacy and safety of adding LCQ908 to Lovaza or fenofibrate.
Interventions
- DRUG Fenofibrate
- DRUG Fish Oil
- DRUG LCQ908
- DRUG Placebo of LCQ908
- DRUG Placebo of fenofibrate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 58 participants |
| Start Date | 2012-06 |
| Est. Completion | 2013-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01594983
The ClinicalTrials.gov registry entry for NCT01594983 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 58 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Fenofibrate is the first listed.
NCT01594983 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01594983 about?
NCT01594983 is a clinical study titled "A Pilot Study to Assess the Efficacy and Safety of LCQ908 Alone and in Combination With Fenofibrate or Lovaza® in Patients With Severe Hypertriglyceridemia". This study is to determine a dose response signal for LCQ908 monotherapy and to assess the efficacy and safety of adding LCQ908 to Lovaza or fenofibrate.
What is the current status of trial NCT01594983?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 58 participants. The study started on 2012-06. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01594983?
The interventions under investigation include: Fenofibrate (DRUG), Fish Oil (DRUG), LCQ908 (DRUG), Placebo of LCQ908 (DRUG), Placebo of fenofibrate (DRUG).
Who is sponsoring clinical trial NCT01594983?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.